MedTrace Logo

Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial

NCT02219893 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2017-05-30

No results posted yet for this study

Summary

The purpose of this study is through a phase I/II clinical trial to assess the safety and toxicity of intraperitoneally administered MOC31PE immunotoxin, given on the 1.postoperative day after cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for peritoneal metastases from colorectal cancer (CRC).

Conditions

  • Colorectal Neoplasms

Interventions

DRUG

MOC31PE Immunotoxin

Patients who meet inclusion criteria will be treated with a single intraperitoneal MOC31PE immunotoxin instillation for 6 hours on the first day after CRS and HIPEC

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Kjersti Flatmark, MD PhD · Oslo University Hospital

  • Svein Dueland, MD PhD · Oslo University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2016-12-10
Completion
2016-12-10

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02219893 on ClinicalTrials.gov